Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study

Lei Lei Wu

News Reporter

Intellia Therapeutics’ CRISPR-based treatment for a rare genetic disease called hereditary angioedema reduced the bouts of swelling associated with the disease in a mid-stage test …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

In­tel­lia’s gene edit­ing ther­a­py suc­ceeds in Phase 2 ge­net­ic swelling con­di­tion study

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study